Market Analysis

Pugatch Consilium is today releasing a new study – Benchmarking Success: Evaluating the Orphan Regulation and its impact on patients and rare disease R&D in the European Union.

Within the context of the European Commission’s Evaluation of the legislationon medicines for children and rare diseases, the study examines whether the EU Orphan Regulation has accomplished its aim of incentivising the development and introduction of new therapies for rare diseases onto the EU market, and explores some of the current and ...

A Pugatch Consilium study released today commissioned by the Biotechnology Innovation Organization (BIO) highlights strategies, policies and best practices that have been successful in creating an environment in which biotechnology innovation can flourish around the world.

The fifth edition of the Building the Bioeconomy report shows the correlation between economies with pro-innovation policy frameworks and those achieving strong biotechnology outputs. By examining 28 different indicators ranging from public policy inputs to biotechnology outputs, the report provides a full and detailed ...

Professor Meir Pugatch spoke at the St. Petersburg International Economic Forum (SPIEF) in the panel: “Life Sciences in 2030: A New Era for Biotechnology” which took place on May 26, 2018 and included the Deputy Ministers of the Ministries of Health, Industry and Trade, and Agriculture of the Russian Federation, as well as Senior Executives of top MNCs in the private sector. Prof. Pugatch presented key highlights of Pugatch Consilium’s research concerning the enabling conditions for developing a competitive bioeconomy ...

In Santiago de Chile, Daniel Coriat shared the results of the BCI 2017 with a distinguished audience at an event hosted by CIF, the local Chilean pharmaceutical trade association. During the event, representatives of the Ministry of Economy and the Ministry of Foreign Affairs highlighted the importance that the BCI tool provides as empirical evidence of the effects of public policy. Here Dan is being interviewed by a renowned journalist in Chile about the BCI:

Professor Meir Pugatch spoke today at the forum “Positioning Taiwan as an Asia-Pacific Biomedical R&D Hub” which took place the International Convention Center in Taipei, and included the Vice President of Taiwan and additional government officials.

Professor Pugatch presented a comprehensive analysis of Taiwan’s competitiveness in the biotech sector, as well as recent improvements to and remaining challenges in Taiwan’s path to leadership in global biotech innovation.

By utilizing a competitive mentality that views policy as instrumental in achieving economic and societal ...

As part of the coverage of the event celebrating 60 years of Afidro where industry, government, patient groups and other stakeholders gathered in Bogota on March 2018, a leading 24-hour news channels in Colombia interviews Pugatch Consilium’s Daniel Coriat on Colombia’s standing in the BCI report. Daniel explains how policies not geared to promote innovation hurt Colombia’s international standing and competitiveness in attracting foreign direct investment.

Professor Meir Pugatch spoke yesterday at the event: “Building a sustainable Policy Framework for Biologics and Biosimilar Medicines in Europe”, which took place at the European Parliament, and included members from the European Commission and organizations such as Medicines for Europe, ESMO and EPF. Professor Pugatch presented the findings of a new study by Pugatch Consilium, commissioned by the European Federation of Pharmaceutical Industries and Associations (EFPIA).

With 38 biosimilar medicines approved and marketed and hundreds of clinical trials on ...

Pugatch Consilium unveiled at the Financial Times Latin America Healthcare & Life Sciences Summit in Sao Paulo Brazil the 2017 Biopharmaceutical Competitiveness & Investment (BCI) Latin America Special Report. This Report is derived from the main 2017 BCI Survey, a global executive opinion survey and index that measures the relative attractiveness of economies to investment from biopharmaceutical research-based companies.